The therapeutic effect of moderately differentiated gastric adenocarcinoma stage 2 cannot be generalized, and it is often closely related to the treatment plan, patient’s own condition and other factors. Generally, moderately differentiated gastric adenocarcinoma stage 2 has rapid progression and has less possibility to be cured, but it can be clinically treated with comprehensive treatment such as surgical resection to improve the quality of survival and prolong the life.
Gastric adenocarcinoma belongs to one kind of gastric cancer, and in general, patients in stage II have to consider the lymphatic metastasis and the infiltration depth of the patient, if the patient invades the superficial myenteric layer, the five-year survival rate after surgery is 50%, the deep myenteric layer is 25%, and the invasion of the plasma membrane, the patient’s five-year post-surgery survival rate is only 10%, and the five-year survival rate is often used to evaluate the survival of patients with tumors. In clinical practice, “five-year survival rate” is often used to assess the survival of tumor patients.
It should be noted that gastric adenocarcinoma patients can reduce the adverse effects of the disease through “early detection, early diagnosis, early treatment”, and many patients may survive for a long time, so it is recommended that patients establish confidence in treatment.